ALX Oncology provides corporate update, key milestones in 2023

ALX Oncology provided a corporate update and highlighted key milestones anticipated in 2023. "2022 marked a successful year of continued clinical and corporate accomplishments for ALX Oncology… 2023 is expected to be an exciting year for ALX Oncology as we look forward to the presentation of data from ASPEN-06, a randomized Phase 2 trial of evorpacept in combination with trastuzumab, ramucirumab and paclitaxel for the treatment of patients with HER2-positive gastric/gastroesophageal junction cancer and presentation of dose optimization results from ASPEN-02, a Phase 1b clinical trial of evorpacept in combination with azacitidine in patients with myelodysplastic syndromes. We are also on track to file an Investigational New Drug, in collaboration with Tallac Therapeutics, for ALTA-002 that will further expand our clinical pipeline beyond evorpacept," said Jaume Pons, Ph.D., Founder, President and Chief Executive Officer of ALX Oncology. Anticipated Milestones in 2023: Presentation of data from a randomized Phase 2 trial of evorpacept in combination with trastuzumab, ramucirumab and paclitaxel for the treatment of patients with HER2-positive gastric/GEJ cancer in the second half of 2023. Presentation of dose optimization results of a Phase 1b clinical trial of evorpacept in combination with azacitidine in patients with MDS in the second half of 2023. Initiation of a Phase 1b dose optimization clinical trial of evorpacept in combination with azacitidine and venetoclax for the treatment of patients with r/r or ND AML in the second half of 2023. Initiation of a Phase 1 trial of evorpacept in combination with antibody drug conjugate, PADCEV, for the treatment of patients with UC in the first half of 2023. Filing an IND for ALTA-002, a SIRPalpha Toll-like receptor agonist antibody conjugate in collaboration with Tallac Therapeutics in the first half of 2023. Expansion of the ADC platform acquired from ScalmiBio to identify clinical development candidates by the second half of 2023.